Statute Details
- Title: Medicines Act 1975
- Act Code: MA1975
- Type: Act of Parliament
- Long Title (summary): Regulates medicinal products and medical advertisements; makes consequential amendments to the Poisons Act 1938
- Current version: Current version as at 27 Mar 2026 (per provided metadata)
- Commencement: Not specified in the provided extract (see Act for commencement provisions)
- Structure: Part 1 (Preliminary) to Part 6 (Miscellaneous and Supplementary), plus Schedules
- Key definitional provision: Section 3 (Meaning of “medicinal product” and related expressions)
- Key regulatory themes: Licensing/certification; permitted sale and supply; prescription-only controls; labelling/packaging; advertising and promotion; enforcement powers and offences
What Is This Legislation About?
The Medicines Act 1975 (“MA”) is Singapore’s foundational statute for regulating medicinal products—covering how such products are licensed, manufactured, imported, sold, labelled, and advertised. In practical terms, it is designed to ensure that medicinal products placed on the market meet safety, quality, and regulatory standards, and that the public is not misled by inaccurate or improper marketing claims.
The Act also establishes a compliance framework that applies across the product lifecycle. It begins with licensing and authorisation for dealing with medicinal products, continues through rules on sale and supply (including prescription-only restrictions), and extends to packaging, labelling, and leaflets. Finally, it regulates promotion and medical advertisements to address the risk that marketing may distort clinical decision-making or encourage inappropriate use.
Although the MA is comprehensive, it is not the only layer of regulation in Singapore’s health regulatory landscape. The Act contains an express carve-out: it does not apply to products categorised and regulated as “health products” under the Health Products Act 2007. This matters for practitioners because classification determines which regulatory regime governs a product and which approvals, labelling, and advertising rules apply.
What Are the Key Provisions?
1) Definitions and scope: “medicinal product” (Part 1)
Section 3 is central because it defines “medicinal product” and related expressions. The definition typically determines whether a product is regulated as a medicine (and therefore subject to licensing, sale restrictions, labelling requirements, and advertising controls) or whether it falls outside the MA (for example, as a “health product” under the Health Products Act 2007). For legal work involving regulatory classification—such as product submissions, enforcement responses, or advertising review—Section 3 is often the starting point.
2) Licensing and authorisation (Part 2)
Part 2 creates the licensing architecture for dealing with medicinal products. It identifies a licensing authority (Section 4) and sets out general rules for dealing with medicinal products (Section 5). It then addresses specific regulated activities, including manufacture and wholesale dealing (Section 6). The Act also provides for exemptions for certain categories of professionals (e.g., pharmacists and practitioners under Section 7), and an exemption in respect of herbal remedies (Section 8), alongside broader general exemptions (Section 9).
For market access, Part 2 includes provisions for a register of medicinal products and import licences (Section 10), and sets out the application process (Section 11) and factors relevant to determination (Section 12). The licensing authority may grant or refuse licences (Section 13), and licences have duration and renewal requirements (Section 14). The Act also contemplates provisional licences (Section 15) and gives the authority broad powers to suspend, revoke, or vary licences (Section 16), including variation on application by the licence holder (Section 17).
Part 2 further regulates clinical trials and medicinal tests on animals (Section 18) and imposes duties to provide information to the licensing authority (Section 19). It also creates an offence framework for breaches of Part 2 (Section 20), including special defences under Section 21. For exporters, the Act provides for certificates for exporters (Section 22). Practitioners should note that licensing and information duties are often the basis for enforcement action even where the product itself is not alleged to be unsafe—non-compliance with regulatory process can be sufficient.
3) Sale, supply, and distribution controls (Part 3)
Part 3 governs how medicinal products may be sold or supplied. It introduces the concept of a general sale list (Section 23). Medicinal products on that list may be sold or supplied under the conditions applicable to that category (Section 25), whereas products not on the general sale list are subject to stricter controls (Section 24). The Act also prohibits sale of medicinal products from automatic machines (Section 26), reflecting concerns about controlled access and appropriate consumer information.
There are professional and herbal-related exemptions (Section 27) and a power to extend or modify exemptions (Section 28). A key consumer-protection provision is prescription-only control (Section 29), which restricts sale or supply of certain medicinal products to cases where a prescription is involved. This is a major compliance area for pharmacies, clinics, and e-commerce operators because it affects dispensing workflows, record-keeping, and staff training.
Part 3 also addresses product integrity and consumer protection. It prohibits sale, supply, or import of certain medicinal products of specified description (and animal feeding stuffs incorporating such products) (Section 30). It contains an adulteration offence (Section 31) and a protection of purchasers provision (Section 32). It further requires compliance with standards specified in monographs in certain publications (Section 33), and provides additional regulatory powers (Section 34). The Part concludes with offences (Section 35), reinforcing that breaches of sale/supply rules are criminally relevant.
4) Labelling, packaging, and identification (Part 4)
Part 4 focuses on how medicinal products are presented to consumers. It requires labelling and marking of containers and packages (Section 44), and regulates leaflets (Section 45). It sets requirements as to containers (Section 46) and provides for distinctive colours, shapes and markings (Section 47). These provisions are often critical in enforcement because inadequate labelling can create a misleading impression of product identity, dosage, or suitability, and can also complicate traceability and recall.
Part 4 includes offences and supplementary provisions (Section 48). For practitioners, labelling compliance is frequently a “high frequency” issue: it is comparatively easy for regulators to verify and can lead to product detention, forfeiture, and prosecution depending on the facts.
5) Promotion, advertising, and medical representations (Part 5)
Part 5 regulates how medicinal products are promoted. Section 49 sets the scope of the Part. Section 50 prohibits false or misleading advertisements and representations. Section 51 prohibits certain medical advertisements, while Section 52 gives the licensing authority powers to regulate advertisements and representations. Section 53 allows the licensing authority to require copies of advertisements. In practice, these provisions are central to legal review of marketing materials, including claims about efficacy, indications, and comparative statements.
Because advertising rules can operate independently of licensing rules (i.e., a product may be licensed but the advertisement may still breach the MA), practitioners should treat advertising compliance as a separate legal workstream.
6) Enforcement powers and offences (Part 6)
Part 6 contains miscellaneous and supplementary provisions, including application rules (Sections 54 and 55), and extensive enforcement powers. Sections 56 to 61 cover rights of entry, powers to inspect, take samples and seize goods and documents (Section 57), supplementary rights (Section 58), seizure or detention (Section 59), forfeiture (Section 60), and disposal of forfeited goods (Section 61). There are also restrictions on disclosure of information (Section 62) and protection for officers (Section 63).
Part 6 includes provisions addressing liability and defences, such as contravention due to default of another person (Section 64), warranty as a defence (Section 65), and offences relating to warranties (Section 66). It also provides for offences by bodies corporate (Section 67). Evidence-related provisions include certificates of analysis (Section 68) and presumptions (Section 69). Procedural matters include service of documents (Section 70) and jurisdiction of District and Magistrate’s Courts (Section 71). The Act also provides for composition of offences (Section 72) and administrative funding arrangements (Section 72A). Finally, it contains regulation-making powers (Section 74) and a key carve-out: Section 77 states the Act does not apply to products categorised and regulated as health products under the Health Products Act 2007.
How Is This Legislation Structured?
The Medicines Act 1975 is organised into six Parts:
Part 1 (Preliminary) sets out the short title and commencement (Section 1), general interpretation (Section 2), and the definition of “medicinal product” (Section 3).
Part 2 (Licences and certificates relating to medicinal products) establishes the licensing authority and the regulatory controls for manufacture, wholesale dealing, import, and related authorisations, including exemptions and offences.
Part 3 (Further provisions relating to dealings with medicinal products) governs sale and supply, including the general sale list, prescription-only rules, restrictions on specified products, adulteration, and consumer protection.
Part 4 (Containers, packages and identification of medicinal products) sets labelling, leaflet, and identification requirements, with offences for non-compliance.
Part 5 (Promotion of sales of medicinal products and medical advertisements) regulates advertising and promotional representations, including prohibitions on misleading claims and powers to require copies of advertisements.
Part 6 (Miscellaneous and supplementary provisions) provides enforcement powers, evidentiary and procedural rules, offences by corporate bodies, and regulation-making authority, plus the carve-out for health products.
The Act also includes First Schedule (Diseases and conditions) and Second Schedule (Amendments to the Poisons Act 1938).
Who Does This Legislation Apply To?
The MA applies to persons and entities that deal with medicinal products in Singapore—particularly those involved in manufacturing, wholesale dealing, importation, sale, supply, and promotion. It also applies to healthcare professionals to the extent they are engaged in regulated dealing, subject to the exemptions in the Act (for example, exemptions for pharmacists and practitioners, and for doctors/dentists/veterinary surgeons).
Practically, the Act affects a wide range of stakeholders: pharmaceutical manufacturers and distributors, importers and exporters, pharmacies and clinics, marketing and advertising teams, and compliance officers responsible for labelling and promotional materials. The carve-out in Section 77 means that if a product is categorised and regulated as a “health product” under the Health Products Act 2007, the MA may not apply to that product—so classification and regulatory mapping are essential.
Why Is This Legislation Important?
The Medicines Act 1975 is important because it provides the legal backbone for Singapore’s medicinal product regulatory regime. It links market access (licensing and registration), product integrity (standards and adulteration controls), consumer-facing safeguards (labelling, leaflets, prescription-only restrictions), and public communications (advertising and promotion rules). For practitioners, this integrated structure means that compliance failures can arise in multiple areas—even if the product is otherwise legitimate.
From an enforcement perspective, Part 6’s inspection, sampling, seizure, detention, forfeiture, and evidentiary provisions give regulators strong tools to investigate suspected breaches. This increases the need for robust documentation and quality systems: licensing records, import documentation, batch/label controls, and advertising approval trails can be crucial in responding to enforcement actions.
Finally, the MA’s interaction with other legislation—especially the Health Products Act 2007 and the Poisons Act 1938 (via consequential amendments)—means that legal advice often requires a “regulatory ecosystem” approach. Determining the correct classification of a product and the correct regulatory pathway is frequently the difference between lawful marketing and a breach that can trigger licensing, seizure, and prosecution risks.
Related Legislation
- Health Products Act 2007 (classification carve-out for “health products”)
- Health Sciences Authority Act 2001 (institutional context for health product regulation)
- Poison-related framework: Poisons Act 1938 (consequential amendments via the Medicines Act’s Second Schedule)
- Dental Registration Act 1999 (professional context for exemptions/regulated activities)
- Birds Act 1965 (relevant where animal-related provisions intersect with medicinal products or animal feeding stuffs)
- Medicines Act 1975 (as the primary statute)
Source Documents
This article provides an overview of the Medicines Act 1975 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.